{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-016767","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2025-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.840426+00:00","generated_at":"2026-05-17T04:45:08.040689+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Regen BioPharma issues 40M shares to CEO and consultant for Phase I trial; shares vest on trial success","bullets":["Issued 20M shares to CEO David Koos for services in planned Phase I trial of HemaXellerate; shares vest upon trial completion.","Issued 20M shares to consultant Dr. Harry Lander for same purpose; same vesting condition.","Total outstanding shares jump to 79,374,704 as of Oct 3, 2025, reflecting ~100% dilution from these grants.","Phase I trial targets drug-refractory aplastic anemia using autologous stromal vascular fraction from adipose tissue.","Shares are restricted and unregistered; vest only upon successful trial completion, otherwise forfeited."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-016767","json":"https://secwatch.observer/filing/0001493152-25-016767.json","markdown":"https://secwatch.observer/filing/0001493152-25-016767.md","text":"https://secwatch.observer/filing/0001493152-25-016767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000149315225016767/0001493152-25-016767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000149315225016767/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:45:08.040689+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}